XGI-131.1.2/MMAE conjugate (Abgenix)

N/A

Report date: 2025/06/11 20:01:15

Base Information

Drug NameXGI-131.1.2/MMAE conjugate (Abgenix)

Drug Alias NameEGFRvIII/AE conjugate (Abgenix)EGFRvIII/auristatin E conjugate (Abgenix)EGFRvIII/monomethylauristatin E conjugate (Abgenix)EGFRvIII/vedotin conjugate (Abgenix)EGFRvIII/MMAE conjugate (Abgenix) +[13]

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Monoclonal antibody conjugateBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody conjugate

Mechanisms of ActionImmunomodulators

TargetsUpdating

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPending (Discontinued)

Highest Status in ChinaN/A

Originator CompaniesAbgenix Incorporated

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesAbgenix Incorporated

Active IndicationsN/A

Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A